{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Stoke Therapeutics, Inc.
Is Stoke Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Stoke Therapeutics, Inc. is considered overvalued with a valuation grade of expensive, reflected in its high P/E ratio of 12 compared to peers, despite a strong year-to-date return of 203.99%.
Stoke Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
Stoke Therapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 12 and a low PEG ratio of 0.09, indicating unique growth potential. The company has delivered impressive returns, outperforming the S&P 500 significantly, while its competitive landscape reveals varied financial health among peers.
Is Stoke Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Stoke Therapeutics, Inc. is considered overvalued with a valuation grade of expensive, despite a strong year-to-date return of 203.99%, as indicated by its low P/E ratio of 12 and other valuation metrics compared to peers.
Is Stoke Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Stoke Therapeutics, Inc. is considered overvalued with a valuation grade of expensive, reflected by a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, despite outperforming the S&P 500 with a year-to-date return of 203.99%.
Stoke Therapeutics Hits New 52-Week High of $37.67, Up 139%
Stoke Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector with a one-year growth of 139.09%. The company, with a market capitalization of USD 1,205 million, showcases effective management and a solid balance sheet, highlighting its competitive position.
Stoke Therapeutics Hits Day High with 15.16% Surge in Stock Price
Stoke Therapeutics, Inc. saw a notable increase in its stock price on October 14, 2025, reaching an intraday high. The company has achieved a remarkable annual return and strong year-to-date performance, reporting significant net profits and sales, while maintaining high institutional holdings and consistent positive results over recent quarters.
Stoke Therapeutics Hits New 52-Week High of $35.08, Up 134.65%
Stoke Therapeutics, Inc. has achieved a new 52-week high of USD 35.08, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 1,205 million, the company showcases strong financial metrics and a solid position in the biotechnology sector.
Stoke Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance
Stoke Therapeutics, Inc. has recently adjusted its valuation, with its stock price reflecting a modest increase. Over the past year, the company has achieved a notable return, significantly surpassing the S&P 500. Key financial metrics indicate a mixed performance compared to industry peers, highlighting the competitive landscape.
Stoke Therapeutics Hits Day High with 11.68% Surge in Stock Price
Stoke Therapeutics, Inc. has seen notable stock activity, achieving significant gains over the past week and month, as well as a remarkable annual return. The company reported positive financial results, including strong operating cash flow and net sales, while maintaining high institutional investor confidence.
Stoke Therapeutics Hits New 52-Week High at $32.40, Up 104.84%
Stoke Therapeutics, Inc. has achieved a new 52-week high of USD 32.40, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 1,205 million, the company demonstrates a favorable P/E ratio and a solid return on equity, highlighting its growth in the pharmaceuticals sector.
Stoke Therapeutics Hits New 52-Week High at $28.00, Up 80%
Stoke Therapeutics, Inc. achieved a new 52-week high of USD 28.00 on October 6, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen an 80.05% stock price increase over the past year and maintains a solid return on equity of 15.67%.
Stoke Therapeutics Hits New 52-Week High of $25.61, Up 71.66%
Stoke Therapeutics, Inc. has achieved a new 52-week high, reflecting a strong performance with a notable increase over the past year. The company, with a market capitalization of USD 1,205 million, demonstrates effective management through its return on equity and favorable valuation metrics compared to industry peers.
Stoke Therapeutics Hits New 52-Week High of $24.97, Up 57.82%
Stoke Therapeutics, Inc. has achieved a new 52-week high, reflecting a strong performance with a notable increase over the past year. The company, with a market capitalization of USD 1,205 million, demonstrates effective management through its return on equity and favorable valuation metrics, despite not offering dividends.
Is Stoke Therapeutics, Inc. technically bullish or bearish?
As of September 5, 2025, Stoke Therapeutics, Inc. has a bullish trend supported by positive MACD signals and strong performance, having returned 26.96% over the past month and 113.06% year-to-date, despite some bearish momentum indicated by the weekly RSI and KST.
Is Stoke Therapeutics, Inc. overvalued or undervalued?
As of August 13, 2025, Stoke Therapeutics, Inc. is fairly valued with a P/E ratio of 12 and has outperformed the S&P 500 year-to-date with a return of 113.06%, despite underperforming over the longer term.
Is Stoke Therapeutics, Inc. overvalued or undervalued?
As of May 13, 2025, Stoke Therapeutics, Inc. is considered an attractive investment due to its undervaluation, with a P/E ratio of 12, an EV to EBITDA of 5.94, and a PEG ratio of 0.09, especially when compared to peers like CorMedix, Inc. at 55.03 and Taysha Gene Therapies, Inc. with a negative P/E, despite a recent stock decline of 18.55% over the past year.
Is Stoke Therapeutics, Inc. technically bullish or bearish?
As of June 3, 2025, the market trend is neutral with mixed signals: the weekly MACD is bullish while the monthly is bearish, indicating divergence, and overall indicators show a lack of clear direction across different time frames.
Who are in the management team of Stoke Therapeutics, Inc.?
As of March 2022, the management team of Stoke Therapeutics, Inc. includes Dr. Seth Harrison (Independent Chairman), Dr. Edward Kaye (CEO), and several Independent Directors: Ms. Jennifer Burstein, Prof. Adrian Krainer, Dr. Arthur Levin, Dr. Garry Menzel, and Ms. Julie Smith. They oversee the company's strategic direction and operations.
What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for genetic diseases, with a market cap of $636.60 million and recent net sales of $159 million. Key financial metrics include a P/E ratio of 12.00 and a return on equity of 14.36%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
